BridgeBio Pharma Total Assets 2018-2024 | BBIO
BridgeBio Pharma total assets from 2018 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
BridgeBio Pharma Annual Total Assets
(Millions of US $) |
| 2023 |
$546 |
| 2022 |
$623 |
| 2021 |
$1,013 |
| 2020 |
$704 |
| 2019 |
$632 |
| 2018 |
$465 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Total Assets
(Millions of US $) |
| 2024-09-30 |
$665 |
| 2024-06-30 |
$794 |
| 2024-03-31 |
$849 |
| 2023-12-31 |
$546 |
| 2023-09-30 |
$655 |
| 2023-06-30 |
$504 |
| 2023-03-31 |
$626 |
| 2022-12-31 |
$623 |
| 2022-09-30 |
$729 |
| 2022-06-30 |
$862 |
| 2022-03-31 |
$813 |
| 2021-12-31 |
$1,013 |
| 2021-09-30 |
$782 |
| 2021-06-30 |
$1,081 |
| 2021-03-31 |
$1,093 |
| 2020-12-31 |
$704 |
| 2020-09-30 |
$788 |
| 2020-06-30 |
$905 |
| 2020-03-31 |
$990 |
| 2019-12-31 |
$632 |
| 2019-09-30 |
$641 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
